An observational study in Hypertension, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Hanmi Pharmaceutical Company Limited · Observational
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 3,500 is above the median of 350 across 1,163 observational studies indexed under Hypertension.
Browse Hypertension studies →Hanmi Pharmaceutical Company Limited is the lead sponsor of 190 studies on the registry; 11 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
General hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follow-up of subjects prescribed medication in a non-intervention study
The change in Systolic Blood Pressure (SBP) relative to baseline
Time frame: the 6-month time
effectiveness of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)
Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 2 and 4 months, and change from baseline in DBP at 6 months
Time frame: 2, 4, 6 months
Prescription patterns of a triple-therapy-based stepwise treatment strategy
Proportion of Participants by Study Drug Dosage at Months 2, 4, and 6
Time frame: 2, 4, 6 months
safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)
Incidence of Adverse Events During the 6-Month Follow-up Period
Time frame: 2, 4 , 6 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited →